Sernova Corp is working to develop a functional cure for type 1 diabetes that could free patients from a lifetime of insulin injections, but despite some early encouraging clinical data and a potentially large commercial opportunity, the company is running low on cash and is competing against a well-capitalized rival.
Key Takeaways
- Sernova is looking to complete a round of financing and would consider a potential partnership with a larger pharmaceutical player, CEO Cynthia Pussinen said.
- The company is working to develop a cell therapy that would work as a functional cure for type 1 diabetes that could free patients from a lifetime of insulin treatments
The small Canadian biotech needs to complete a round of financing and would consider a potential partnership with a larger
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
